MiMedx Concludes Enrollment for Phase 2B Study of Osteoarthritis (OA) of the Knee

by NASDAQ Market News September 21, 2020

NASDAQ Market News
Click here to email author

Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs

Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

Ads